Jun 6 |
Seres, indebted and in need of cash, agrees to sell microbiome pill to Nestle
|
Jun 6 |
Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023
|
Jun 6 |
Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science
|
May 13 |
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2024 Earnings Call Transcript
|
May 11 |
Seres Therapeutics, Inc. (MCRB) Q1 2024 Earnings Call Transcript
|
May 9 |
Seres Therapeutics First Quarter 2024 Earnings: US$0.28 loss per share (vs US$0.56 loss in 1Q 2023)
|
May 9 |
Seres Therapeutics Inc (MCRB) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ...
|
May 8 |
Seres Therapeutics Reports Q1 2024 Earnings: Surpasses Revenue Estimates
|
May 8 |
Seres Therapeutics GAAP EPS of -$0.27 beats by $0.07
|
May 8 |
Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
|